Evotec SE (EVO)
| Market Cap | 945.19M -18.8% |
| Revenue (ttm) | 925.65M -1.1% |
| Net Income | -121.54M |
| EPS | -0.68 |
| Shares Out | 177.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,894 |
| Open | 2.630 |
| Previous Close | 2.620 |
| Day's Range | 2.600 - 2.645 |
| 52-Week Range | 2.308 - 4.800 |
| Beta | 1.24 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+166.16%) |
| Earnings Date | Apr 8, 2026 |
About EVO
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and c... [Read more]
Financial Performance
In 2025, Evotec SE's revenue was 788.37 million, a decrease of -1.08% compared to the previous year's 796.97 million. Losses were -103.52 million, -47.21% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to one analyst, the rating for EVO stock is "Strong Buy" and the 12-month stock price target is $7.0.
News
Evotec (EVO) Q3 2025 Earnings Call Transcript
Evotec (EVO) Q3 2025 Earnings Call Transcript
Evotec SE (EVOTF) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue Challenges
Evotec SE (EVOTF) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue Challenges
Q4 2025 Evotec SE Earnings Call Transcript
Q4 2025 Evotec SE Earnings Call Transcript
Earnings Scheduled For April 8, 2026
Companies Reporting Before The Bell • Beasley Broadcast Group (NASDAQ: BBGI) is projected to report earnings for its fourth quarter. • RPM International (NYSE: RPM) is projected to report quarterly ...
MAK Capital Urges Evotec To Pursue U.S. Listing For Just Biologics
WASHINGTON (dpa-AFX) - MAK Capital is urging Evotec SE to take its U.S. subsidiary, Just Biologics, public and to accelerate its cost-cutting measures. They believe more decisive steps are necessa...
What To Expect From Evotec SE (XTER:EVT) Q4 2025 Earnings
What To Expect From Evotec SE (XTER:EVT) Q4 2025 Earnings
Evotec vows to further engage with investor MAK, who demanded change
Evotec said on Tuesday it would continue a dialogue with investor MAK Capital, which has published a list of changes it wants the German biotech firm to make.
Evotec SE: Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Strengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitabilityIndustry veteran brings more than 30 years...
Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Strengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitability Industry veteran brings more than 30 years o...
EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evotec SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 02.04.202...
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026
HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) will hold a webcast and conference call to announce its financial results for the fourth quarter an...
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer
HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer.
EQS-AFR: Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Evotec SE / Preliminary announcement on the disclosure of financial statements Evotec SE: Preliminary announcement of the publication of quarterly repor...
EQS-AFR: Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Evotec SE / Preliminary announcement on the disclosure of financial statements Evotec SE: Preliminary announcement of the publication of financial repor...
Evotec SE: Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
The program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yieldsManufacturing proce...
Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
The program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yields Manufacturing process...
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer Transformative moment i...
Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Evotec SE (NASDAQ: EVO). The investigation focuses on Evotec executive of...
Evotec Restructuring Aims To Improve Profitability After Transition Year
Evotec SE (NASDAQ: EVO) stock is trading lower on Tuesday.
Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities Investment enables ten new J.MD™ projects encompassing molecular optimization including, but not limi...
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment HAMBURG, DE / ACCESS Newswire / Janua...
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just ...
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome Milestone payment to Evotec expected upon first dosing of first study participant in early 2026 HAMBU...
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to ...
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerati...